Quadrant Capital Group’s AbCellera Biologics ABCL Stock Holding History

Quadrant Capital Group’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,220	Closed	-$4.26K	–	1248
2026 Q1	$4.26K	Sell	1,220 -312	-20%	-$1.12K	﹤0.01%	2389
2025 Q4	$5.24K	Buy	1,532 +103	+7%	+$460	﹤0.01%	2360
2025 Q3	$7.19K	Buy	+1,429	New	+$6.3K	﹤0.01%	2248
2025 Q2	–	Sell	-21,946	Closed	-$48.9K	–	1340
2025 Q1	$48.9K	Sell	21,946 -32,763	-60%	-$94K	﹤0.01%	1723
2024 Q4	$160K	Buy	54,709 +24,871	+83%	+$69.3K	0.01%	801
2024 Q3	$77.6K	Buy	29,838 +28,786	+2,736%	+$79.8K	0.01%	1222
2024 Q2	$3.11K	Buy	1,052 +604	+135%	+$2.29K	﹤0.01%	2405
2024 Q1	$2.03K	Sell	448 -1,555	-78%	-$7.93K	﹤0.01%	2505
2023 Q4	$11.4K	Buy	2,003 +1,121	+127%	+$5.2K	﹤0.01%	2015
2023 Q3	$4.06K	Hold	882	–	–	﹤0.01%	2226
2023 Q2	$5.7K	Buy	+882	New	+$6.02K	﹤0.01%	2175

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Quadrant Capital Group's ABCL Position: Q2 2026 in Review

Quadrant Capital Group sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 1,220 shares — an estimated $4.26K sold.

Quadrant Capital Group first reported a position in ABCL in Q2 2023 and held it in 11 quarters. The position peaked at $160K in Q4 2024. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Quadrant Capital Group reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 1,220 AbCellera Biologics shares in Q2 2026, an estimated $4.26K.
Quadrant Capital Group first reported a position in AbCellera Biologics in Q2 2023 and held it in 11 quarters.
Quadrant Capital Group's AbCellera Biologics position peaked at $160K in Q4 2024.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.